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Specific immune responses to thymus-dependent  antigens  involve multiple stages 
of cell  interaction.  Initiation  of an  immune  response  requires  the  presentation  of 
antigen by macrophages, as well as the successful interaction of multiple subsets of T 
cells.  In the mouse, both antigen recognition and the production of antigen-specific T 
cell factors by helper  (Th) 1 or suppressor  (Ts)  T  cells appear to be controlled  by/- 
region genes of the major histocompatibility complex (H-2)  (1, 2). Immune response- 
associated  (Ia)  molecules found on most B  cells,  and  to varying degrees on macro- 
phages and T  cells, are encoded by genes in the I-A and I-E subregions and may well 
be  products  of immune  response  (Ir)  and/or  immune  suppressor  (Is)  genes  (3-5). 
Successful T-B cell collaboration requires identity of genes, or their products,  in the 
I-A subregion (3). 
The development of inbred strains of mutant mice has proven useful in ascribing 
specific gene fractions to particular genetic loci within the regions and subregions of 
the H-2 complex (6).  The B6.C-H-2  b'~l~ (bml2)  strain is of particular interest in that 
it bears a presumptive single gene mutation altering the A~ chain, encoded in the I-A 
subregion, and is characterized by changes in serologically defined Ia determinants, 
by strong  graft  rejection,  and  by mixed  lymphocyte response between  parent  and 
mutant  (7-14). Mice of the bml2 strain have impaired immune responses, relative to 
the parental strain C57BI/6Kh (B6), to beef insulin  (15), to H-Y antigen (11), and to 
the alpha chain of human hemoglobin  (16).  In contrast,  bml2  immune responses to 
other  antigens,  such  as  poly(L-Tyr,L-Glu)-poly(DL-Ala)--poly(L-Lys) [(T,G)-A--L], 
poly(L-Phe,L-Glu)-poly(DL-Ala)--poly(L-Lys) [(Phe,G)-A--L],  and  poly(L-His,L-Glu)- 
poly(DL-Ala)--poly(L-Lys) [(H,G)-A--L], do not differ markedly from parental B6 mice 
(11,  15, 17). Although the immune responsiveness to beef insulin, H-Y antigen, human 
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alpha-hemoglobulin,  (T,G)-A--L,  (Phe,G)-A--L,  and  (H,G)-A--L  map  to  the  I-A 
subregion, alteration of the A~ molecule (12)  does not affect all of these responses. 
Primary  immune  responses  to  the  thymus-dependent  synthetic  antigens  poly- 
(Glu~I'yr  5°)  (GT) and poly(Gln6°Ala3°Tyr 1°)  (GAT)  are controlled by/-region genes 
(18-21).  GAT stimulates the development of Th in responder strains (H-2 a'b'd haplo- 
types)  and Ts in nonresponder strains (H-2 p'q'* haplotypes)  (21). On the other hand, 
>40 inbred strains of mice have been shown to be nonresponders to GT (18,  19, 22, 
23).  Nonresponsiveness  to  GAT  and  GT  is  not  a  result  of a  general  B  cell  defect 
because all strains make a good antibody response to these antigens when coupled to 
the immunogenic carrier molecule, methylated  bovine serum albumin  (MBSA)  (18, 
20). GT-nonresponder strains of mice can be further classified as either GT-suppressor 
(H-2 d'k~ haplotypes), in which administration of GT renders the animals incapable of 
responding to subsequent  immunizations with GT-MBSA,  or as GT nonsuppressors 
(H-2 s'b'q haplotypes)  (18,  19,  24-26).  Mice of the H-2 b'a'k haplotypes,  when injected 
with GT, produce a first-order T cell-derived suppressor factor (GT-TsF1) that induces 
a second, distinct subset of Ts (Ts2) in H-2  *'a~' haplotype mice (24, 26). 
In  this study we have  investigated  GAT  and GT responsiveness  of mutant  bml2 
mice. We find that,  in contrast to the parental  B6, bml2 mice are responders to GT 
and low or nonresponders to GAT and are unable to produce GT-TsFx. 
Materials and Methods 
Animals.  BALB/cCum (H-2  a) mice were purchased from Cumberland View Farms, Clinton, 
TN. B10.A(5R)  (5R; H-2i~), B6 (H-2b), BALB/cKh (H-2d), and (bml2) mice as well as F1 and 
F2 hybrid mice derived from these strains, were bred in the authors' colonies at Northwestern 
University, Chicago, IL. Mice used in these studies were 2-4 mo old and were maintained on 
standard laboratory chow and water ad lib. 
Antigens.  GT, lot 9, originally purchased from Miles Laboratories, Inc., Elkhart, IN was the 
generous gift of Dr. Baruj Benacerraf, Harvard Medical School, Boston, MA. Poly(Glu6°Ala  ~) 
(GA), with average 4:5,000 mol wt, was purchased from Miles Laboratories, Inc. GAT, lot  1, 
and MBSA were purchased from Vega Biochemicals, Tucson, AZ. In some experiments, GAT, 
lot 31F5040, from Sigma Chemical Corp., St. Louis, MO was used with identical results. GAT, 
GT, GA, and their MBSA complexes were prepared as previously described (26). 
Immunizations.  Mice were immunized with either 100 #g GT or 10 #g GT as GT-MBSA in 
Maalox (aluminum-magnesium hydroxide gel; Wm. Roher, Ft. Washington, PA) and Bordadla 
pertussis, intraperitoneally, as adjuvant.  7 d  later, the number of GT-specific plaque-forming 
cells (PFC) per spleen was determined. For delayed-type hypersensitivity (DTH) and in vitro 
proliferation studies, mice were immunized subcutaneously at the base of the tail with 20 #g of 
GAT contained in  50 #l  of complete Freund's adjuvant  (containing H37Ra)  as previously 
described (27). 
GT-TsFPreparation.  Lymphoid cell extracts were prepared from GT-primed mice as previ- 
ously described (24,  25).  Briefly, B6 or bml2 mice were intraperitoneally primed with  100 #g 
GT in Maalox 3 d before they were killed. Single cell suspensions of their spleens were prepared, 
adjusted to 6 X  108 cells/ml in Hanks' balanced salt solution (HBSS), and sonicated at 50 W 
for 5 rain by a Sonifier Cell Disruptor (Ultrasonic Industries, Westbury, NY) equipped with a 
microtip. Sonicated material was centrifuged at 40,000 g for 45 min at 4°C and the resultant 
supernates stored at -85°(] until use. 
Spleen Cell Cultures.  Single cell suspensions of unimmunized mice were prepared aseptically 
and washed once with HBSS. Cells were resuspended to a final concentration of 16 X 10  cells/ 
ml in Mishell-Dutton medium (28) containing 5 ×  10 -b M  2-mercaptoethanol and  10% fetal 
calf serum (FCS; lot 07;  Bioserum, Inc., Great Neck, NY)  (25).  GT (2.5-10 #g), GA (10/zg), 
GAT (2.5-10 #g), or GT (2.5 #g) as GT-MBSA antigens were added to 0.5 ml of cell suspension 
in individual wells of a  multiwell culture plate (76-033-05;  Linbro Chemical Co., Hamden, 598  POLY(GLUS°,ALA  4°)  RESPONSIVENESS  IN bml2 MICE 
CT) as indicated in the Table legends.  Extracts from GT-primed B6 or bml2 mice were added 
at  final concentrations as indicated  in Table legends.  Cultures were incubated  for 5 d  in a 
humidified atmosphere of 83% Nz, 10% CO2, and 7% 02 at 37°C and fed daily with a mixture 
of 50% nutritional cocktail and 50% FCS (28). 
Hemolytic Plaque Assay.  7 d after in vivo injection of antigen, or 5 d after culture initiation, 
spleen cells were washed three times in HBSS, and PFC responses were assayed using sheep 
erythrocytes (SRBC) coupled with the cross-reacting copolymer, GAT (29). GA-, GAT-, and 
GT-specific PFC were determined by subtracting the number of PFC detected in the presence 
of suitable dilution of GAT from the number of PFC detected on GAT-SRBC in the absence 
of the specific  inhibitor. All assays  were performed in duplicate and the number of PFC per 
culture are reported. 
Induction and Elicitation of Delayed-Type Hypersensitivity (DTH)  Responses.  6-7 d after immu- 
nization, mice were challenged by intracutaneous injection of the dorsal surface of the ear with 
10/xg of GAT (contained in  10 #1 of saline)  using a  100-/xl Hamilton syringe fitted with a 30- 
gauge needle.  24 h after antigen challenge, increases in ear thickness were determined using an 
engineer's micrometer, and the results  were expressed in units of 10  -4 in.  (27). 
In  Vitro T  Cell Proliferation.  After determination  of in  vivo ear swelling,  draining lymph 
nodes  (inguinal  and  periaortic)  were used  as a  source of cells  for determining  the level  of 
antigen-induced T  cell  proliferation.  4 ×  10  s cells were cultured  in flat-bottomed microwell 
plates  in  a  vol of 0.2  ml  of modified  Click's medium  (30) supplemented  with  fresh  0.5% 
syngeneic mouse serum. Cultures were stimulated with the indicated doses of GAT or CA. The 
plates were incubated  in a  humidified atmosphere of 5% CO2,  95% air for 120 h, and were 
pulsed with  t #Ci of [aH]thymidine (6 Ci/mM;  Research Products International Corp., Mr. 
Prospect, IL) for the final 24 h. Cultures were harvested with a semiautomatic sample harvester, 
and measurements of trichloroacetic acid-insoluble radioactive material were determined in a 
Beckman liquid scintillation  counter  (Beckman Instruments,  Inc., Mr.  View, CA). Cultures 
were performed in triplicate and results expressed as A cpm [(mean cpm of antigen-containing 
cultures) -- (mean cpm of antigen-free-"nil"-cultures)], as previously described (27). 
Results 
Elicitation  of Prima~y  GT Responses  in  bml2  Mice.  In >40  inbred  strains  of mice, 
representing 23 different H-2 haplotypes and 15 different non-H-2 backgrounds tested 
by primary  or secondary  injection  of GT,  none  responded  to GT  (18,  19,  22,  23). 
Merryman and Maurer  (22)  and  Debr~ et  al.  (18)  demonstrated  that some outbred 
Swiss mice responded to GT, although it was not possible to attribute GT responsive- 
ness to a  particular haplotype or locus. Although it is possible to selectively inbreed 
GT  responder  Swiss  mice  to  ultimately  identify  the  locus  or  loci  involved  in  GT 
responsiveness,  such  procedures,  though  straightforward,  are  both  time-consuming 
and costly. Rather than trying to produce a GT-responder phenotype by backcrossing 
and selection, we chose to look at inbred strains that differ from parental strain mice 
only by mutation  at  one or a  few  loci.  Preliminary  in  vitro  screening  experiments 
showed that bml2 mice appeared to make a  primary PFC response to GT. As shown 
in Table I, this was confirmed in vivo (group a) when the injection ofbml2 mice with 
100 btg GT resulted in a primary antigen-specific PFC response. In contrast, injection 
of parental  B6 mice (group B) with GT does not elicit  a  primary PFC response.  B6 
mice  injected  with  10 /xg GT  as  GT-MBSA  (group  C)  show  a  response  of similar 
magnitude to the brnl2 GT response. In fact, the bml2 anti-GT response is significant 
(P =  0.001)  when  compared with  nonresponder-nonsuppressor  B6  (group  B)  mice 
and suppressor BALB/c (group D), 5R (group E), and (BALB/c ×  B6)FI, (C ×  B6)F1, 
(group G) mice. One could always make the argument that as the bml2 mutation was 
first detected in a  (B6 ×  C)F1 mouse, BALB/c passenger genes may account for GT 
responsiveness. In fact, this cannot be the case since (C ×  B6)F1 mice are nonresponders LEI,  MELVOLD,  MILLER, AND WALTENBAUGH 
TABLE  I 
GT Responsiveness In Vivo 
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Number  Antigen-specific PFC 
Group  Strain  Antigen*  of mice  per spleen:~ 
per group 
arithmetic mean :1: SE 
A  bml2  GT  9  20,750 :l: 5,520 
B  B6  GT  13  2,090 "4- 685 
C  B6  GT-MBSA  8  22,120 :t: 1,345 
D  BALB/c  GT  5  <250 
E  5R  GT  4  <250 
F  (C × B6)Fx  GT-MBSA  5  9,020 +  1,910 
G  (C × B6)F1  GT  5  1,030 :t: 780 
H  (bml2 × BALB/c)Fx  GT  3  6,000:1:1,995 
I  (bml2 × 5R)FI  GT  5  22,400 :l: 5,340 
* Mice were intraperitoneally  immunized with either 10/~g  GT as GT-MBSA or 100 #g GT in Maalox and 
B. pertussis as adjuvant. 
* 7 d after GT or GT-MBSA injection, the number of antigen-specific PFC per spleen was determined. 
bml2 (group A) GT responsiveness differs significantly  (P <  0.005, as determined by ANOVA)  from 
groups B, D, E, and G. 
to GT  (group  G).  Furthermore,  in  (responder ×  suppressor)F1 hybrid mice of both 
sexes, GT-responsiveness is dominant as seen in groups H  and I of Table I. 
Responsiveness of bm l 2 and B6 Spleen Cells to GT and GA Tin  Vitro.  During the course 
of  our  preliminary  screening  experiments,  we  noticed  that  bml2  mice  were  not 
responsive to GAT in vitro, as illustrated in Table II. Cultures of B6 spleen cells are 
responsive to GAT in a  2.5-10 #g dose range (in our laboratory 10 #g is optimum for 
all CAT responder strains), whereas they are nonresponsive to GT over a  similar dose 
range, although  they respond to 2.5 #g GT  as GT-MBSA. bml2 mice, on  the other 
hand, respond to GT over a  2.5-10 #g dose range, while remaining totally unable to 
make  an  anti-GAT  PFC  response.  These  data suggest  that  the  mutation  allowing 
bml2 mice to respond to GT also has an adverse effect on GAT PFC responses. 
Failure ofbml2 Mice to Make GT-TsF1.  The GT-MBSA PFC responses of B6 (H-2  b) 
mice  cannot  be  suppressed  by  preimmunization  with  GT.  B6  mice  do,  however, 
produce GT-TsF1  as a  consequence  of GT  priming,  although  they  cannot  be  sup- 
pressed by this  or any  other  GT-TsFx, because  they  are  deficient  in  the  ability to 
produce  functional  Ts2  (24-26).  Although  bml2  mice  are  able  to  respond  to  GT 
challenge, it is possible that  they, likewise, make a  GT-TsFx. The data in Table III 
show  that  B6  mice make a  GT-TsF1  that  suppresses >80%  of the GT-MBSA  PFC 
response of BALB/c mice that normally generate Ts2 as a  consequence of exposure to 
B6 GT-TsF1  (24).  Lymphoid cell extracts from GT-primed bml2 mice show no such 
suppressive activity. In  fact, experiment  2  of Table III shows that  bml2 GT-extract 
markedly enhances the BALB/c GT-MBSA PFC response. 
PFCResponsesof (BALB/c  ×  bml2)FlandF2MicetoGT,  GA, andGATIn  Vitro.  The 
data in Table I show that bml2-related GT responsiveness is inherited as a  dominant 
trait. The data in Table II indicate that bml2 is a GAT-nonresponder strain. Previous 
reports  (20,  21)  have shown  that  responsiveness to GAT  is inherited as a  dominant 
trait: a  (suppressor ×  responder)F1 hybrid animal responds to GAT. bml2 mice appear 
to be GT responders and GAT  nonresponders, whereas  BALB/c mice are the exact 600  POLY(GLU~°,ALA  ~)  RESPONSIVENESS  IN  bml2 MICE 
TABLE  II 
Responses of bml 2 and B6 Spleen Cells to GTand GA T In  Vitro 
Experiment  Antigen 
Antigen-specific PFC per 
culture* 
C57BL/6  bm l 2 
#g 
10.0 GAT  1,010  <20 
5.0 GAT  920  <20 
2.5 GAT  270  <20 
10.0 GT  <20  2,540 
5.0 GT  <20  2,760 
2.5 GT  <20  840 
2.5 GT-MBSA  1,270  1,170 
20.0 GAT  ND,  50 
10.0 GAT  ND  40 
2.5 GAT-MBSA  ND  1,410 
20.0 GT  ND  1,410 
10.0 GT  ND  1,200 
2.5 GT-MBSA  ND  690 
* GAT- or GTospecific PFC responses to GAT, GT, and GT as GT-MBSA or 
GAT as GAT-MBSA per culture of B6 or bm12 spleen cells on day 5  of 
culture. 
Not determined. 
TABLE  III 
Effect of Extracts from GT-primed  bml2 Mice on BALB/c GT-MBSA 
Responses In  Vitro 
Extract* 
GT-specific PFC per cuhure$ 
Experiment  1  Experiment 2 
Control GT-MBSA response  1,170  2,685 
B6GT-TsF1 
1:400  <25  440 
1:800  <25  480 
bml2 GT-extract 
1:400  975  3,740 
1:800  1,250  5,620 
* B6 or bml2 mice were injected with 100 #g GT in Maalox; 3 d later, extracts 
were  prepared  from  their  spleens and  thymuses, filter-sterilized,  and  the 
extract equivalent to  1.5  X  106 cells (1:400)  or  7.5 ×  105 cells (1:800)  was 
added at culture initiation. 
GT-specific  PFC  responses of BALB/c  spleen  cells  to  2.5  #g GT  as  GT- 
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opposite  (18-21).  We asked whether  (BALB/c  ×  bml2)F1 hybrid mice are responders 
to both GT and GAT. The data in Table IV show that  (BALB/c  ×  bml2)F1 mice are 
able  to  respond  equally  well  to  in  vitro  immunization  of GT  or  GAT  and  to  the 
closely related polymer GA. One would predict that if a  single or multiple, but closely 
linked, mutation(s)  affects PFC responsiveness to GT  and CAT,  then the intercross of 
(BALB/c  ×  bml2) F1 should  result  in  [GT nonresponder-GAT  responder] :[GT/GAT 
responder]:[GAT  nonresponder-GT  responder]  F2 hybrid  mice  in  the  ratio  of 1:2:1. 
(BALB/c  X  bml2)F2 mice were  immunized  in  vitro with  GT,  GA, or GAT,  (Table 
IV). Of the 21  mice so far tested,  5  were GAT  responders,  but  nonresponders  to GT 
(as  compared  with  GT-MBSA  controls),  12  were  responsive  to  both  GAT  and  GT, 
whereas  4  were nonresponders  to GAT,  although  remaining  responsive to GT.  Mice 
that were nonresponsive to GAT  were also nonresponders  to GA. Our observed 5:12:4 
TABLE  IV 
PFC Responsiveness of (BALB/c X  bml2)F2 Mice to GT, GA, and GAT In Vitro 
Animal  Antigen-specific  PFC per culture* 
Sex  H-2 genotype  number  GT  GA  GAT  GT-MBSA 
(BALB/c × bml2)Fl  Known 
1  M  3,900  3,340  3,140  810  d/bm 12 
2  F  420  420  400  400  d/bm 12 
3  F  520  460  440  440  d/bm 12 
(BALB/c × bml2)F2  Presumptive§ 
1  M  845  1,950  1,625  400  d/bm 12 
2  M  565  940  1,090  975  d/bm 12 
3  M  20011  1,005  875  1,400  d/d 
4  M  1,120  1,010  1,200  870  d/bml2 
5  M  1,145  905  1,065  830  d/bm 12 
6  M  940  1,060  825  730  d/bin 12 
7  M  800  835  765  1,160  d/bm 12 
8  M  375  <20  <20  560  bm 12/bm 12 
9  M  345  <20  <20  340  bm 12/bm 12 
10  M  360  355  335  340  d/bm 12 
11  F  695  960  585  530  d/bm 12 
12  F  600  725  350  625  d/bm 12 
13  F  90  1,125  605  675  d/d 
14  F  1,390  1,725  1,155  1,175  d/bml2 
15  F  830  1,010  1,130  1,185  d/bml2 
I6  F  260  25  25  320  bm 12/bm 12 
17  F  540  70  <20  260  bm 12/bm 12 
18  F  <15  210  235  190  d/d 
19  F  240  210  195  195  d/bm 12 
20  F  <15  270  255  210  d/d 
21  F  <15  495  375  360  d/d 
* Spleen cells from normal (BALB/c × bml2)Fl  or F2 mice were cultured in the presence of 10 pg GT, GA, 
GAT or 2.5 #g GT as GT-MBSA; antigen-speciflc PFC per culture were determined on day 5. 
:~ (BALB/c × bml2)Fa  were the parents of the (BALB/c X bml2)F2  mice, below. 
§ H-2 genotype as predicted from a [GT nonresponder]:[GAT-GT responder]:[GAT nonresponder]  ratio of 
1:2:1. Actual F2 data show a 5:12:4 ratio which yields a X  2 value of 0.5238 (P ffi 0.773). 
I[ Boldface PFC values indicate low or nonresponder as compared with control (GT-MBSA) PFC responses. 602  POLY(GLUS°,ALA  4°)  RESPONSIVENESS IN bml2 MICE 
ratio does not  differ significantly  (X  z ~- 0.524,  P  =  0.773)  from the predicted  1:2:1 
ratio. Yet, because of the small sample size, our data do not exclude a  9:3:3:1  ratio 
that one would predict if the gene(s) responsible for GT responsiveness and GAT/GA 
unresponsiveness segregated as two independent loci. 
Cell-mediated Immune  Responses  to  GA  and  GAT in  bin12  Mice.  The  data  shown  in 
Tables II and IV above indicate  that  bin12 mice respond to GT and not  to GA or 
GAT in the PFC assay. We asked whether this responder/nonresponder  PFC status 
of bml2 is generalizable to other immunological phenomena. Accordingly, GAT PFC 
responder [B6, BALB/c, (C ×  B6)Fx]  and GAT PFC nonresponder  (bin12) mice were 
immunized with 20 ~g GAT emulsified in Freund's complete adjuvant at the base of 
the tail. 6 d  after immunization, the mice were challenged with  10/Lg GAT (in  10 #1 
phosphate-buffered  saline)  subcutaneously  in  the  dorsal  surface  of the  ear.  DTH 
reactions were assayed by ear swelling 24 h  after challenge.  The draining  inguinal 
and periaortic lymph nodes were cultured in the presence of 5 or 0.5/~g GAT for 96 
h, whereupon T  proliferative responses were measured by tritiated thymidine incor- 
poration. In addition, GAT-specific splenic PFC of these same mice were enumerated 
on  the  day of DTH  measurement.  Data  from these  experiments  show  GAT  PFC 
responder  mice  [B6,  BALB/c,  and  (C  ×  B6)Fll  show  very  good  DTH  and  T 
proliferative responses as well as anti-GAT PFC responses (Table V). bin12 mice, on 
the other hand, show significantly diminished DTH responses and background levels 
of GAT-specific PFC, but no decrease in the T  proliferative response to either 5 or 0.5 
/xg of GAT in vitro. These results indicate that bm 12 mice are GAT nonresponders for 
PFC and DTH responses, while showing T  proliferative responses equal to that of B6 
mice. There are several important points that have to be dealt with in regard to these 
findings.  First,  the  ear  swelling  assay  is  not  a  measurement  of anti-GAT  DTH 
responses, but rather is a  result of an Arthus-type reaction, and lack of ear swelling 
would  be a  result of the lack of antibody that would mediate the immune complex 
reaction.  Experiments performed in GAT-responder mice (not shown)  indicate that 
ear swelling is not antibody-mediated; no ear swelling is seen at 4 h postchallenge, the 
TABLE V 
DTH, PFC and Tp~ozif  Responses to GA T in bml 2 
Num- 
ber  Ear swell-  GAT-specific 
Strain  Antigen*  of  ing~:  P value  PFC per spleen§  P value 
mice 
T  cell proliferation 
5,0/~g GAT  0.5/~g GAT 
P  P 
cpmll  value  cpmll  value 
X  104m 
B6  "nil"  3  3.8 ±  10  --  1,130 ±  80  ..... 
B6  GAT  4  65.9 ±  5.1  <:0.001  22,000 "+ 2,470  <0.001  34,520 ±  13,710  --  22,870 ±  10,570  -- 
bm 12  GAT  6  15.4 ::l: 2.0  0.001¶  1,560 ±  640  0.717"*  35,960 ~  l 1,450  0.962  32,640 ±  13,690  0.580 
BALB/c  GAT  4  40.7 ±  4.9  <0.001  28,540 ±  12,130  <0.001  ND:~:~  ND 
(C x  B6)F~  GAT  3  38.2 "¢- 3.2  <0.001  27,000 ±  2,410  <0.001  ND  ND 
* Mice were injected with 20/.~g GAT emulsified in complete Freund's adjuvant containing H37Ra subcutaneously  at the base of the tail. 
Mice were challenged with 10,~g soluble GAT in 10 #l NaCI intraeutaneously  in the dorsal surface of the ear, 6 d after immunization, and responses 
measured by ear swelling 24 h later. 
§ PFC responses were determined  7 d after immunization. 
II See Materials and Methods for immunization, culture, and methods for determining net cpm. 
¶ Comparison of B6 and bml2 DTH responses to GAT are significantly different  (P <  0.001) as determined by ANOVA. 
** Comparison of B6 and bml2 PFC responses to GAT are significantly different  (P <  0.001) as determined by ANOVA. 
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usual time period for appearance of Arthus. We feel that the lack of 4-h ear swelling 
and the ability to transfer the reaction by cells (data not shown) rules out an Arthus- 
type reaction. Further experiments are in progress to clarify this matter. Second, bml2 
mice show T  proliferation to GAT, although they are unable to make an anti-GAT 
PFC  or  DTH  response.  This  would  indicate  that  the  proliferating  T  (Tp~olif) cell 
population is distinct from the DTH cell, raising the possibility that the genetic lesion 
in bml2 mice is not a  result of the lack of the Tp~o~ cell is generally held to be a  Th 
cell. The lack of both GAT PFC and DTH responses in bml2 may not be a  result of 
a  lack of Tp,ol~, but of the lack of a suitable target for the Th. The data in Table II 
show that bml2 mice can make very good anti-GAT-MBSA PFC responses, indicating 
that they possess GAT-specific B cells. One would then have to hypothesize that there 
may be an  intermediate  cell  between  the  Th  and  B  cell,  such  as  a  Th2  cell.  Our 
laboratories are currently investigating this possibility. 
Discussion 
Mutant  or abnormal  genetic  variants have been  extremely useful  in  the  genetic 
characterization  of many biological systems. The bml2 variant arose as a  gain/loss 
type spontaneous  mutation  like  other  mutants  of the  bm  series.  However,  bml2  is 
unique among bm mutants in that it is the only strain so far described with a mutation 
localized  to  the  /-A-subregion  of the  H-2  complex.  The  bml2  mutant  exhibits  a 
number of functional  differences relative  to  the  parental  B6  strain  with  regard  to 
graft rejection (7), Ia antigen expression (8,  12, 13, 31, 32), mixed lymphocyte reaction 
(8), and loss of responsiveness to various antigens under Ir gene control  (11,  14-17, 
33).  This  study  is  the  first  to  report  the  establishment  of responder  status  as  a 
consequence  of mutation  (to GT), while causing loss of responsiveness to a  closely 
related antigen  (GAT). Our data show that, because of a  mutation affecting theA~ 
chain of the I-A molecule, bml2 mice have the ability to respond to GT and lost the 
ability to make a  PFC or DTH response to the closely related copolymer GAT. This 
is in sharp contrast to the parental B6 strain, which is a GT nonresponder and a GAT 
responder. Furthermore, this is the first report of an inbred GT-responder strain. 
Previous reports (18, 22) have shown that some outbred Swiss mice were responsive 
to GT immunization,  however, this trait  could  not  be directly attributable  to any 
particular H-2 or non-H-2 genes. In the present study, bml2 mice have been shown to 
be PFC responders to GT in contrast to parental B6 mice. The bml2 and B6 strains 
differ presumably only by the A~ chain of the I-A molecule. Therefore, we are able to 
ascribe GT responsiveness to the I-A subregion and, presumably, to the I-A molecule 
of H-2. At the same time, we have observed a  greatly diminished  ability to make a 
GAT-speeific DTH responses or GA/GAT-specific PFC responses by bml2. GA/GAT 
responsiveness must also result  from the same gene encoding the A~ molecule. Our 
observation confirms and extends the recent report of Baxevanis et al. (34) by mapping 
GA responsiveness to the A~ molecule encoded by the I-A subregion. GT responsiveness 
is transmitted as an autosomal dominant trait  (Tables I and IV), much the same as 
has been reported for GAT responsiveness (19). GT responsiveness does not preclude 
GAT responsiveness  in  (C  ×  B6)F1  mice, Table  IV,  suggesting  that  the  responses 
associated with the AO molecules of both parental haplotypes are seen in the F1 hybrid 
mice. This observation is in accord with classical observations that Ia antigens are co- 
dominantly expressed in F1 animals (4).  The segregation of GT and GA/GAT PFC 604  POLY(GLUr'°,ALA  4°)  RESPONSIVENESS IN bml2 MICE 
responses in (BALB/c ×  brnl2)Fz  mice is exactly what one would predict with single 
or two closely linked genes (Table IV). In fact, the prediction ofa [GT nonresponder- 
GAT responder]:[GAT-GT responder]:[GAT nonresponder-GT responder]  ratio  of 
1:2:1  is not significantly different (X  2 square ~- 0.524, P  -- 0.773)  from the observed 
5:12:4 ratio if only one gene or closely linked genes were involved. However, because 
of the limited sample size, we cannot exclude the possibility of two unlinked genes 
yielding  a  9:3:3:1  [GAT-GT  responder]/[GAT  nonresponder-GT  responder]/[GT 
nonresponder-GAT responder]/[GAT-GT nonresponder] ratio. Since evidence exists 
for I-A control of GA/GAT responsiveness (2, 34) and GT responsiveness (this paper), 
it is most likely that GT-GA/GAT responsiveness is controlled by a  single locus or 
two closely-linked loci. We are currently making the appropriate backcrosses to resolve 
this question. 
Previous studies have shown a heterogeneity in Is gene defects in GT-nonsuppressor 
strains  of mice  (24,  25).  Briefly, GT-nonsuppressor mice can  be  divided  into  two 
categories depending upon which ls  gene they lack.  H-2  a haplotype mice lack the 
ability to produce a suppressor T  cell factor (GT-TsFI) after GT injection, but can be 
readily suppressed when injected with GT-TsF1. In H-2  b haplotype mice, such as B6, 
GT injection results in GT-TsF1 production, although these mice lack a  functional 
target cell for the factor (i.e.,  Ts2).  In the present study, we asked whether bml2, a 
GT-responder strain,  can  produce a  GT-TsFa like parental  B6  mice. The data  in 
Table III above show that  bin12 mice do not produce GT-TsF1. Since B6 GT-TsF1 
bears antigenic determinants of the I-J  b subregion (24), our present data indicate that 
a  gene in  the I-A subregion  influences production of I-jb-bearing GT-TsF1.  If the 
bin12 variant bears a single mutation affecting only that gene encoding the Ap chain 
of the I-A molecule, then this same gene or its product(s)  must influence gene(s) or 
the cells expressing gene products of the I-J subregion. 
Although bin12 mice are low or nonresponders to GAT by either the PFC or DTH 
responses, they must also be classified as GAT responders in the T  cell-proliferation 
assay, when compared with parental B6 mice (Table V). Since we see a close parallel 
between  lack of DTH  responses and  PFC  against  GAT in  bml2 mice, it  could be 
argued that the ear swelling reaction reflects an Arthus-type reaction and not DTH. 
We  don't  believe this  to  be  the  case  as  we  see  no  significant  ear  swelling  above 
background within 4 h postchallenge (data not shown). In either case, lack of PFC or 
DTH responses in brnl2 mice cannot be predicted by the T  cell-proliferation assay. A 
precedent already exists for the disparity between humoral immunity and proliferative 
responses to antigens under/r gene control. Merryman and Maurer (22) reported that 
H-2  b'a'f'k'r'~ haplotype mice make antibody responses to GA, whereas H-2  j'p'q do not. 
Baxevanis et  al.  (34),  using the  very same  antigen  in  a  T  cell proliferation assay, 
reported that H-2  r'~ mice are nonresponders to GA. From our present data, we propose 
several possible mechanisms  that  may account  for the discrepancy between T  cell 
proliferative responses and PFC vs. DTH responses:  (a) The Tp~o~ is not the efferent 
Th cell (Theu) for PFC response, suggesting that the Tpro~ is an afferent Th  (The) 
cell. This would  necessitate a  two-step mechanism  for help much the same as has 
been demonstrated for Ts, where a Tsl cell induces or stimulates a Ts2 via TsF1 (26). 
In  fact, several investigators  have proposed  models  involving multiple  Th cells in 
regulatory cellular circuits for humoral immunity (35,  36)  and DTH responses (37). 
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tritiated  thymidine  is  not  under Ir  gene  control  and  is  not  affected by  the  bml2 
mutation. The Th,n, on the other hand, would appear to be the site of the functional 
It/Is gene lesion(s); this cell would be defective in its ability to deliver an adequate 
help signal to the DTH effector cell or to the B cell. Lack of functional Thee activity 
could be a result of either clonal deletion similar to the model recently proposed by 
Schwartz  (38)  or  of active  suppression  of Three  function.  Clonal  deletion  would 
necessitate that pre-Thett clones bearing receptors for GT/GAT plus A# in B6/bml2 
mice mimic anti-self and are selectively deleted during ontogeny. It must be restated 
that the bml2 does not appear to have a defective GAT-specific B cell, as bml2 mice 
make a  very good GAT-specific PFC response to GAT-MBSA (Table II).  (b)  If the 
Tp~o~ is  the  same  as  the  Th  cell  for a  PFC  response,  then  it  must  be  unable  to 
communicate an effective help signal to the DTH effector cell or the B cell--indicating 
that the A# molecule is involved in direct T-T cell (in DTH) or T-B cell (in PFC) 
interactions,  and  may serve as  a  recognition  unit  for this  collaboration.  (c)  GAT 
proliferative response in bm 12 mice may not reflect the proliferation of T  cells directly 
involved in T  cell help, rather they may be cells involved in Ts induction. One would 
predict that the Ts-inducer cell proliferation would yield a GAT-specific TsF in bml2 
mice. Experiments currently in  progress are addressing the  question whether bml2 
mice produce GAT-TsFa. On the hand, bml2 mice do not make GT-TsF as parental 
B6  mice  do  (Table  III),  indicating  that  the  proposed  GT-specific Ts-inducer cell 
population must express the A# molecule. 
Several  ramifications  of the  bml2  genetic  variation  on  GAT  and  GT  immune 
responses become apparent. The alteration of the Ag molecule in brnl2 causes loss of 
primary GAT PFC and DTH responsiveness, while, at the same time, resulting in GT 
PFC responsiveness. That a single mutation would have opposite effects on immune 
responses  to closely related  antigens  suggests  a  bottleneck in  the cellular immune 
mechanisms responsible for GT and GAT responses. We know that bml2 mice can 
make  a  B  cell response to GAT-MBSA,  indicating  that  these  mice do not  possess 
defective B cells (Table II). Furthermore, Fathman et al. (14) have shown that (bml2 
×  B6)Fx spleen cells can effectively present GAT to (B6 ×  A)F1 GAT- or (T,G)-A--L- 
reactive T  cell clones. They concluded that alteration of theA~ chain does not modify 
the T  cell restriction site for some of the GAT epitopes, indicating normal antigen 
presentation  (i.e., macrophage)  function for GAT. Similarly, Pierce and Kapp  (39, 
40)  and Clark et al.  (41)  have demonstrated that  macrophages from nonresponder 
mice  can  stimulate  GAT-specific helper T  cells  in  responder mice.  Since  neither 
macrophages nor B cells appear to be responsible for GAT/GT responsiveness, we 
must assume that the bottleneck lies in the T cell component of the immune response. 
The evidence presented in this study suggests that the bottleneck is not at the level of 
the Tp~o~ cell.  Strassmann  et al.  (37)  have proposed two distinct Th in  (T,G)-A--L 
DTH responses, one cell acting at the education stage (hence The) and the other at 
the efferent phase (Three) of DTH. With regard to GAT responsiveness, we propose 
that bml2 mice are functionally deficient in Theee, although they possess normal The. 
This GAT-specific Theee would be the efferent Th cell (or cells) for both DTH and 
PFC reactions, and functionally distinct from the Th~ (or Tprout) cell. The GT-specific 
Th~ and Theee  appear to function normally in the bml2 strain, whereas one or both 
of these cells may be deficient in the parental B6 strain. On the other hand, the B6 
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Evidence for this comes from the observations that B6 mice treated with cyclophos- 
phamide can make a  PFC response upon secondary challenge with GT in vivo (C. 
Waltenbaugh, unpublished observation) and that in vitro treatment of B6 spleen cells 
with  monoclonal  anti-I-J  b  antibody  allows  the  development  of GT-specific  PFC 
responses (42). We propose the following model to account for GAT/GT responsive- 
ness for both B6 and bml2 strains:  (a) Both B6 and bml2 strains possess normal Th~ 
(i.e., Tp,olif) for GAT (bml2 proliferative T  cell responses are, as yet, undetermined for 
GT).  (b)  That  the  A~  molecule  is  necessary  for  T-T  cell  interaction/recognition 
between the Tp~om and its target cell(s), either Tsl or Then, for both GAT and GT. (c) 
Both GAT- and GT-specific Ts and Then recognize different regions of the same A~ 
chain of the I-A molecule with opposite effects. We propose that  the GAT-specific 
Theft must recognize the same portion of  the At~ molecule as GT-speeific Tsl. Therefore, 
the  mutation  that  would  impair  the  generation  of GAT-specific Th~e~ would  also 
render  the  bml2 animal  incapable  of generating GT-TsF1. Conversely, a  different 
region of the At~ chain (or the A~ chain) of the I-A molecule, unaffected by the bml2 
mutation,  must  be responsible for generation of both GT-specific Then and  GAT- 
specific Tsx. If B6 GT-specific Theft cells are weak or inefficient, they may be easily 
suppressed by B6 GT-TsF1 directly without requiring amplifying Tsz cells. Pretreat- 
ment of B6 mice with either anti-I-J  b or cyclophosphamide may remove this low-level 
suppression,  thus  allowing  B6  mice  to  make  an  anti-GT  PFC  response.  We  are 
currently investigating the possibility that both the bml2 and B6 strains are capable 
of making GAT-TsF1, indicating that neither strain has a defect in its ability to make 
GAT-TsF1, as the model would predict. In the  (BALB/c ×  bml2)F1 animal, we see 
the  dominance  of response  to  both  GT  and  GAT,  which  is  in  accord  with  the 
observations that in (responder X suppressor)F1 hybrids, response predominates (2, 4, 
20).  Thus, our model would predict  that  different antigens  may be recognized by 
different T  cell populations in the context of the same Ia gene product. 
Summary 
The development of inbred strains of mutant mice has proven useful in ascribing 
specific gene functions to particular genetic loci within the regions and subregions of 
the  H-2 complex. The B6.C-H-2 nmI2 (bml2)  strain  is of particular interest  in  that, 
compared  to  parental  C57BI/6Kh  (B6)  mice,  it  bears  a  presumptive  single  gene 
mutation altering the A~ chain encoded by the I-A subregion. Our data show that 
bml2 mice have gained the ability to respond to poly(Glu~-I'yr  ~) (GT) and have lost 
the ability to make plaque-forming cell or delayed-type hypersensitivity responses to 
the closely related copolymer, poly(Glu6°Alaa°Tyr  1°) (GAT), although  retaining the 
ability to mount a GAT-specific T cell proliferative response. This is in sharp contrast 
to the parental B6 strain, which is a GT nonresponder and a GAT responder. Thus, 
this study is the first to report the establishment of responder status as a consequence 
of mutation. Possible mechanisms accounting for the gain/loss of GT/GAT respon- 
siveness in the context of a two-step helper T  cell model are discussed. 
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